These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 18424366)

  • 1. N-terminal acetylation protects glucagon-like peptide GLP-1-(7-34)-amide from DPP-IV-mediated degradation retaining cAMP- and insulin-releasing capacity.
    John H; Maronde E; Forssmann WG; Meyer M; Adermann K
    Eur J Med Res; 2008 Feb; 13(2):73-8. PubMed ID: 18424366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
    Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
    Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.
    Green BD; Gault VA; Mooney MH; Irwin N; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
    J Mol Endocrinol; 2003 Dec; 31(3):529-40. PubMed ID: 14664713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity.
    Green BD; Mooney MH; Gault VA; Irwin N; Bailey CJ; Harriott P; Greer B; O'Harte FP; Flatt PR
    J Endocrinol; 2004 Mar; 180(3):379-88. PubMed ID: 15012592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity.
    Deacon CF; Knudsen LB; Madsen K; Wiberg FC; Jacobsen O; Holst JJ
    Diabetologia; 1998 Mar; 41(3):271-8. PubMed ID: 9541166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39).
    Green BD; Mooney MH; Gault VA; Irwin N; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
    Metabolism; 2004 Feb; 53(2):252-9. PubMed ID: 14767880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid.
    Green BD; Gault VA; Flatt PR; Harriott P; Greer B; O'Harte FP
    Arch Biochem Biophys; 2004 Aug; 428(2):136-43. PubMed ID: 15246869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro.
    Gallwitz B; Ropeter T; Morys-Wortmann C; Mentlein R; Siegel EG; Schmidt WE
    Regul Pept; 2000 Jan; 86(1-3):103-11. PubMed ID: 10672909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineered beta-cells secreting dipeptidyl peptidase IV-resistant glucagon-like peptide-1 show enhanced glucose-responsiveness.
    Islam MS; Rahman SA; Mirzaei Z; Islam KB
    Life Sci; 2005 Jan; 76(11):1239-48. PubMed ID: 15642594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice.
    O'Harte FP; Mooney MH; Kelly CM; McKillop AM; Flatt PR
    Regul Pept; 2001 Jan; 96(3):95-104. PubMed ID: 11111014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of glucagon-like peptide-1(7-36)amide and somatostatin-14 in RINm5F cells and in the perfused rat pancreas.
    Göke R; Fehmann HC; Richter G; Trautmann M; Göke B
    Pancreas; 1989; 4(6):668-73. PubMed ID: 2573056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1.
    Lee SH; Lee S; Youn YS; Na DH; Chae SY; Byun Y; Lee KC
    Bioconjug Chem; 2005; 16(2):377-82. PubMed ID: 15769092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.
    Mentlein R; Gallwitz B; Schmidt WE
    Eur J Biochem; 1993 Jun; 214(3):829-35. PubMed ID: 8100523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.
    Hansen L; Deacon CF; Orskov C; Holst JJ
    Endocrinology; 1999 Nov; 140(11):5356-63. PubMed ID: 10537167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent.
    Doyle ME; Greig NH; Holloway HW; Betkey JA; Bernier M; Egan JM
    Endocrinology; 2001 Oct; 142(10):4462-8. PubMed ID: 11564711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
    Green BD; Gault VA; O'Harte FP; Flatt PR
    Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion.
    Deacon CF; Plamboeck A; Møller S; Holst JJ
    Am J Physiol Endocrinol Metab; 2002 Apr; 282(4):E873-9. PubMed ID: 11882507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary adenylate cyclase-activating peptide (PACAP): assessment of dipeptidyl peptidase IV degradation, insulin-releasing activity and antidiabetic potential.
    Green BD; Irwin N; Flatt PR
    Peptides; 2006 Jun; 27(6):1349-58. PubMed ID: 16406202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity.
    Kim KR; Rhee SD; Kim HY; Jung WH; Yang SD; Kim SS; Ahn JH; Cheon HG
    Eur J Pharmacol; 2005 Jul; 518(1):63-70. PubMed ID: 16106524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationships of glucagon-like peptide-1(7-36)amide: insulinotropic activities in perfused rat pancreases, and receptor binding and cyclic AMP production in RINm5F cells.
    Watanabe Y; Kawai K; Ohashi S; Yokota C; Suzuki S; Yamashita K
    J Endocrinol; 1994 Jan; 140(1):45-52. PubMed ID: 8138751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.